荣昌生物制药(烟台)股份有限公司由王威东先生领导的烟台荣昌制药股份有限公司和留美科学家房健民博士于2008年共同创立。荣昌生物总部位于中国山东省烟台市,在中国和美国均设有实验研究机构和办事处。荣昌生物致力于发现、开发、生产和商业化同类首创、同类最佳的生物药物,针对自身免疫、肿瘤、眼科等重大疾病领域创制出一批具有重大
荣昌生物:688331.SH HKEX stock code: 荣昌生物:09995.HK Investors Announcements and Notices Financial Reports Listing Documents 292025.05 Next Day Disclosure Return 292025.05 COMPLETION OF PLACING OF H SHARES 272025.05 VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL ...
Telitacicept is the first biological drug for dual-target treatment of systemic lupus erythematosus in the world. In March 2021, the new drug marketing application of Telitacicept for the treatment of SLE passed the priority review and approval process. As an urgently needed clinical drug with o...
Our vision is to become a leading world-class bio-pharmaceutical company in both China and the world. We have also established our Scientific Advisory Board which currently comprises four renowned professors and key opinion leaders in the areas of our research and development, including Dr. Pei Ga...
BOSS直聘为您提供2025年烟台荣昌生物制药最新招聘信息,7个烟台岗位正在直招牛人,烟台荣昌生物制药招聘岗位类别有:质量研究员(博士)、实习生招聘、药物合成研究员、制剂设备工程师 (MJ001697)、生产设备计算机化工程师,进入网站与荣昌生物制药的Boss在线直接开聊吧!
荣昌生物是一家始终坚持创新、不断追求科学卓越的公司。在这样一个机遇与挑战并重的平台上,每个人都能够得到足够的尊重与信任。它的开放与包容能够吸引更多优秀人才的加入,海内外业务的扩展,让我有更多机会深入了解行业。同时也让我看到周围更多优秀的同事,他们怀抱激情和理想,始终以专业的态度对待各项工作,散发各自的闪...
For more information about RemeGen, please visit:www.remegen.com Forward-Looking Statements Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the possible utility or application of the Company's technologies to develop therapeutic agent...
荣昌生物制药(烟台)股份有限公司成立于2008年07月04日,位于中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号,目前处于开业状态,在中国和美国均设有实验研究机构和办事处。荣昌生物致力于发现、开发、生产和商业化同类首创、同类最佳的生物药物,针对自身免疫、肿瘤、眼科等重大疾病领域创制出一批具有重大临床价值...
荣昌生物制药(烟台)有限公司成立于2008年,是一家专注于生物创新药物研究与开发的现代化高新技术企业。公司总部位于山东省烟台经济技术开发区荣昌生物医药园区,占地面积约200亩,拥有一支由国家“千人计划”专家、“泰山学者”、海外专家等具有数十年生物新药研发经验的国际高端人才领衔的科研团队。公司依托新一代生物药物开...
Disitamab Vedotin is China’s first original antibody drug conjugate (ADC) developed by RemeGen. It is the first Chinese ADC drug to be dually recognized as a breakthrough therapy by the FDA of US and NMPA of China. Its gastric cancer and urothelial cancer indications were approved for marke...